Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

USCOM Ltd Completes Pulsecor Asset Purchase and Acquires New BP+ Central Blood Pressure Device


Monday, 17 Jun 2013 08:02pm EDT 

USCOM Ltd announced completion of the purchase of all assets of Pulsecor Limited in exchange for five million fully paid ordinary shares of Uscom Limited (UCM). Pulsecor Limited was valued at approximately NZD2.9million at its last capital raising in May 2011 prior to regulatory approvals, and is Uscom’s first international corporate acquisition. Pulsecor’s BP+ product, currently being sold internationally, has US Food and Drug Administration (FDA) 510k, European CE mark and Australian Therapeutic Goods Administration (TGA) approval. Distribution of the BP+ device will be through Uscom’s growing global distribution network plus a network of new distribution partners. 

Company Quote

0.2
 --
19 Nov 2014